Eikon Therapeutics Inc. Common Stock (EIKN)
Stock · NASDAQ · Health Care
$7.42as of 10/16/2026
Price chart
Active signals
High Beta45.8%
Resistance level
$8.97
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers a…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 384
- Website
- eikontx.com/
Fundamentals
- 1-day range
- $7.01$7.69
- Market cap
- $498.62M
- P/E (trailing)
- —
- P/E (forward)
- -1.19
- EPS (trailing)
- $-10.10
- Dividend yield
- —
- Beta
- 1.95
- Avg. volume
- 506.6K
52-week range
$6.45$17.4
Next earnings: August 13, 2026 · EPS estimate $-1.46
Forecasts
5 analyst ratings
Buy 83%
Hold 8%
Sell 8%
1-year price forecast
High
$32
+331.3%
Median
$29
+290.8%
Low
$4
-46.1%
Eikon Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
- VALNValneva SE American Depositary Shares$5.61▼ 5.08%Market cap $491.51MP/E —$2.03$5.15
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $5.61 | ▼ 5.08% | $2.03$5.15 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23benzinga · 10/16/2026
- Alpha Buying: Follow the Money From NVIDIA and MerckBenzinga · 9/24/2026
- Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
89.2K
Disposed
0
- Column Group IV GP, LP · September 3, 2026 · Buy89.2K @ $11.56
Institutional Ownership
March 31, 2026
- Total shares held
- 23.58M
- Total value held
- $226.27M
- Institutional holders
- 48
Top holders this quarter
- Unknown3.84M
- Unknown3.32M
- Unknown1.94M
- Unknown1.67M
- Unknown1.32M
- Unknown1.22M
- Unknown1.14M
- Unknown1.02M
- Unknown975.8K
- Unknown969.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
EIKN sees institutional buying following NVIDIA and Merck moves
Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.
EIKN sees institutional buying following NVIDIA and Merck moves. Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.